期刊文献+

帕金森病模型研究进展 被引量:4

Recent Progress in Models of Parkinson's Disease
下载PDF
导出
摘要 帕金森病(Parkinson’s disease,PD)是一种常见于中老年的神经退行性疾病,其特征性的病理改变为黑质纹状体多巴胺能神经元选择性缺失以及胞浆内涵物Lewy小体的形成。PD的发病机制目前尚不清楚,但已经明确环境因素和遗传因素在PD的发病中起重要作用。为阐明PD的病理生理机制,进一步探索新的治疗手段,迫切需要与PD密切相似的模型。本文将就目前发展的各种PD模型做一综述。 Parkinson's disease (PD) is a progressive neurodegenerative disorder that is primarily characterized by the degeneration of dopaminergic neurons in the nigrostriatal pathway. The pathology of PD is typified by the presence of cytoplasmic inclusions (Lewy bodies ) containing a-synuclein and ubiquitin. The pathogenesis of PD is not completely understood but environmental and genetic factors are thought to play important roles. To understand the pathophysiology of PD, and to develop novel therapies for improved symptomatic management, it is important to have relevant disease models. In this review, we summarize the available in vivo and in vitro models of PD and discuss their value.
出处 《中国比较医学杂志》 CAS 2008年第7期63-67,共5页 Chinese Journal of Comparative Medicine
基金 国家自然科学基金(30672151) 中日友好医院重点科研基金(20052016)
关键词 帕金森病 模型 LEWY小体 Parkinson's disease (PD) Model Lewy bodies
  • 相关文献

参考文献24

  • 1Fahn S, Sulzer D. Neurodegeneration and neuroprotection in Parkinson disease[J]. Neuro Rx, 2004, 1(1):139- 154.
  • 2Fornai F, Lenzi P, Gesi M, et al. Recent knowledge on molecular components of Lewy bodies discloses future therapeutic strategies in Parkinson' s disease [ J]. Curr Drug Targets CNS Neurol Disord, 2003, 2(3) : 149 - 152.
  • 3Allam MF, Del Castillo AS, Navajas RF. Parkinson's disease risk factors: genetic, environmental, or both[J]? Neurol Res, 2005, 27 (2) :206 - 208.
  • 4Logroscino G. The role of early life environmental risk factors in Parkinson disease: what is the evidence [J ]? Environ Health Perspect,2005, 113(9) : 1234 - 1238.
  • 5Lester J, Otero-Siliceo E. Parkinson's disease and genetics [ J ]. Neurologist, 2006, 12(5) :240 - 244.
  • 6Litvan I, Halliday G, Hallett M, et al. The etiopathogenesis of Parkinson disease and suggestions for future research [ J ]. J Neuropathol Exp Neurol, 2007, 66(4) :251 - 257.
  • 7Langston JW, Ballard P, Tetrud JW, et al. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis[J]. Science, 1983, 219(4587) :979 - 980.
  • 8Watanabe Y, Himeda T, Araki T. Mechanisms of MPTP toxicity and their implications for therapy of Parkinson's disease [ J ]. Med Sci Monit, 2005,11(1):RA17-23.
  • 9Kitamura Y, Kakimura J, Taniguchi T, et al. Protective effect of talipexole on MPTP treated planarian, a unique parkinsonian worm model[J]. Jpn J Pharmacol, 1998, 78(1) :23 - 29.
  • 10Smeyne RJ, Jackson-Lewis V. The MPTP model of Parkinson' s disease[J]. Brain Res Mol Brain Res, 2005, 134(1) :57- 66.

同被引文献39

引证文献4

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部